Evidence map›Paper›PMID 25961772›Full record

Trial reportBone marrow transplantation2015

Prognostic understanding, quality of life and mood in patients undergoing hematopoietic stem cell transplantation.

A El-Jawahri, L Traeger, K Kuzmuk, J Eusebio, H Vandusen, T Keenan, J Shin, E R Gallagher, J A Greer, W F Pirl and 8 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05190653 (Early Integration of Palliative and Supportive Care for Patients and Family Caregivers Undergoing Hematopoietic Stem Cell Transplantation or Chimeric Antigen Receptor T-Cell Therapy), which is not on this map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05190653 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Early Integration of Palliative and Supportive Care for Patients and Family Caregivers Undergoing Hematopoietic Stem Cell Transplantation or Chimeric Antigen Receptor T-Cell Therapy: A Prospective Pragmatic Randomized Clinical Trial

TypeinterventionalSponsorAlberta Health Services, CalgaryRan2022 to 2025Enrolled152ConditionsLeukemia, Lymphoma, Multiple Myeloma, Blood CancerArmsEarly palliative and supportive care
3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. A systematic review of coping skill interventions to reduce anxiety and depressive symptoms among adults with hematologic malignancies.European journal of oncology nursing : the official journal of European Oncology Nursing Society · 2022
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Fatigue and quality of life in the early phase after allogeneic hematopoietic stem cell transplantation: dynamics and the impact of graft-versus-host disease.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

A El-Jawahri1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
L Traeger1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
K KuzmukDepartment of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
J Eusebio1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
H Vandusen1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
T Keenan1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
J Shin1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
E R Gallagher1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
J A Greer1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
W F Pirl1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
V A Jackson1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
K K Ballen1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
T R Spitzer1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
T A Graubert1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
S McAfee1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
B Dey1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
Y-B A Chen1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
J S Temel1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.

Funding

Optimizing Palliative and End of Life Care for Patients with CancerK24CA181253 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI TEMEL, JENNIFER SUE · 2014 to 2018
$737k
NCI NIH HHS K24 CA 181253NCI NIH HHS K24 CA181253
6 · The paper itself

Abstract

Little is known about how patients undergoing hematopoietic stem cell transplantation (HCT) and their family caregivers (FC) perceive their prognosis. We examined prognostic understanding in patients undergoing HCT and their FC and its relationship with quality of life (QOL) and mood. We conducted a longitudinal study of patients (and FC) hospitalized for HCT. We used a questionnaire to measure participants' prognostic understanding and asked the oncologists to estimate patients' prognosis prior to HCT. We assessed QOL and mood weekly and evaluated the relationship between prognostic understanding, and QOL and mood using multivariable linear mixed models. We enrolled 90 patients undergoing (autologous (n=30), myeloablative (n=30) or reduced intensity allogeneic (n=30)) HCT. About 88.9% of patients and 87.1% of FC reported it is 'extremely' or 'very' important to know about prognosis. However, 77.6% of patients and 71.7% of FC reported a discordance and more optimistic prognostic perception compared to the oncologist (P<0.0001). Patients with a concordant prognostic understanding with their oncologists reported worse QOL (β=-9.4, P=0.01) and greater depression at baseline (β=1.7, P=0.02) and over time ((β=1.2, P<0.0001). Therefore, Interventions are needed to improve prognostic understanding, while providing patients with adequate psychological support.

Indexed as

AffectHematopoietic Stem Cell TransplantationQuality of LifeAdultAgedAllograftsAutograftsDepressionFemaleHematologic NeoplasmsHumansMaleMiddle AgedPrognosis

Identifiers

PMID25961772
PMCPMC4526323

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.